Teva New Case Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva Pharmaceutical Industries Limited To Contact The Firm

New York, New York--(Newsfile Corp. - October 1, 2020) -  Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating claims against Teva Pharmaceutical Industries Limited ("Teva" or the "Company") (NYSE: TEVA) and reminds investors of the November 23, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA. There is no cost or obligation to you.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6455/65000_94b4d16cc40329ff_001.jpg

You can also contact Faruqi & Faruqi partner James Wilson toll free at 877-247-4292 or 212-983-9330 (Ext. 1310) or by emailing him at jwilson@faruqilaw.com to discuss your rights and options.

A lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania on behalf of all those who purchased Teva securities between October 29, 2015 and August 18, 2020 (the "Class Period"). The case, Halman Aldubi Provident and Pension Funds Ltd. v. Teva Pharmaceutical Industries Limited et al, No. 20-cv-04660 was filed on September 23, 2020.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6455/65000_94b4d16cc40329ff_002.jpg

As detailed below, the lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Teva had made substantial illegal kickback payments to charitable foundations to cover Medicare co-payment obligations of patients taking Copaxone; (2) accordingly, Teva's revenues derived from Copaxone were in part the product of unlawful conduct and thus unsustainable; (3) the foregoing misconduct subjected Teva to a foreseeable risk of heightened regulatory scrutiny and enforcement, as well as reputational harm, when the truth became known; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

Specifically, on August 18, 2020, the United States Department of Justice ("DOJ") issued a press release announcing that it had filed a complaint against Teva under the False Claims Act. Specifically, "[t]he government alleges that, from 2007 through 2015, Teva paid The Assistance Fund (TAF) and Chronic Disease Fund (CDF) with the intent and understanding that the foundations would use Teva's money to cover the Medicare co-pays of patients taking Copaxone. During the same period, Teva raised the price of Copaxone from approximately $17,000 per year to over $73,000 per year."

On this news, Teva's American depositary receipt ("ADR") price fell $1.11 per ADR from its previous close on August 17, 2020, or 9.6%, to close at $10.48 per ADR on August 18, 2020, on unusually heavy trading volume.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Teva's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/65000

info